Menlo Park, CA, December 17, 2015 – 5AM Venture Management LLC (5AM) of Menlo Park and Boston is pleased to announce senior leadership promotions and the addition of two new members to the firm. Kush Parmar, M.D., Ph.D. has been named a Managing Partner and Paul Stone, J.D. has been named a Partner. Louis A. Tartaglia, Ph.D., is joining 5AM as CEO of the “4:59 Initiative”, which focuses on forming and incubating companies based on breakthrough ideas. Dr. Tartaglia will also serve as a 5AM Executive-in-Residence. More information on the “4:59 Initiative” can be found below. In addition, Mira Chaurushiya, Ph.D. has joined the 5AM team as an Associate.
Dr. Parmar becomes 5AM’s fourth Managing Partner since its inception. “We’re delighted to recognize the significant value Kush has brought to 5AM over the past five years,” said Scott Rocklage, Managing Partner. “His extensive scientific understanding of medicine, combined with strong leadership skills and sound investment judgment, makes him an ideal Managing Partner. We look forward to the many contributions he will make to 5AM.”
Dr. Parmar joined 5AM’s Boston office in 2010 from Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the joint Harvard-MIT Health Sciences and Technology Program. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School. Dr. Parmar serves or has served as a Director or Observer on the boards of Achaogen (AKAO), Arvinas, Audentes Therapeutics, Cleave Biosciences, Envoy Therapeutics (acquired by Takeda), Homology Medicines, Novira Therapeutics (acquired by J&J), Pulmatrix (PULM) and scPharmaceuticals. He serves on the Scientific Advisory Councils of Princeton’s Department of Molecular Biology and the Grace Wilsey Foundation. Dr. Parmar is also a Fellow of the Kauffman Fellows Society.
In 2009 Mr. Stone joined 5AM as General Counsel & Chief Operating Officer in the Menlo Park office, coming from Ethos Pharmaceuticals, where he was General Counsel and SVP, Intellectual Property. Previously he served as SVP, General Counsel and Chief Patent Counsel at Ilypsa (acquired by Amgen) and as Chief Patent Counsel at Symyx Technologies. “Paul has made significant contributions to 5AM and our portfolio companies over the past six years,” said Andrew Schwab, Managing Partner. “In addition to his internal legal and operational responsibilities, Paul has been an important member of the 5AM team, directly adding value to our portfolio companies.” Mr. Stone received a J.D. from the University of Wisconsin Law School in 1995 and practiced as a Patent Attorney at Senniger, Powers, Leavitt & Roede. Mr. Stone received a degree in Chemical Engineering, University of Wisconsin – Madison in 1985, and served as a Naval Officer on the USS NIMITZ. Mr. Stone serves or has served as a Director or Observer on the boards of Cidara Therapeutics, Homology Medicines, IDEAYA Biosciences, Kinestral Technologies, Rennovia and Wildcat Discovery.
Mira Chaurushiya, Ph.D. joined 5AM’s Menlo Park office in 2015 coming from Genentech, where she was a Post-doctoral Fellow in the Department of Physiological Chemistry studying mouse models of cancer and stem cells. During her post-doctoral work at Genentech, she served as a consultant to 5AM and Roche Ventures. Dr. Chaurushiya received her Ph.D. in Biological Sciences from the University of California, San Diego in conjunction with the Salk Institute for Biological Studies, where she was awarded the Martin Kamen Thesis Prize in Biochemistry. She received a B.A. in Biology from Carleton College.
4:59 and Leadership
To lead the growth of 5AM’s internal therapeutic company incubation efforts, known as the “4:59 Initiative”, Lou Tartaglia has been appointed as CEO of 4:59 One and will be based in the Boston office. Dr. Tartaglia will drive 5AM’s efforts to form and incubate biotech companies based on breakthrough ideas while leveraging the resources of the entire 5AM team. 4:59 efforts already underpin 5AM-founded companies Cidara (CDTX), Homology Medicines, and IDEAYA Biosciences. Dr. Tartaglia previously served as President & CEO of Solstice Biologics following seven years as a Partner at Third Rock Ventures. While at Third Rock, he played a number of company building roles including as Interim Chief Scientific Officers at Agios Pharmaceuticals (AGIO), Editas Medicine, Rhythm Pharmaceuticals and Zafgen Pharmaceuticals (ZFGN). Previously he was Vice President of Metabolic Diseases and Vice President (Head) of New Ventures at Millennium Pharmaceuticals. Dr. Tartaglia holds a Ph.D. in Biochemistry from the University of California in Berkeley and a B.S. in Chemistry from the State University of New York at Albany.
About 5AM Ventures
Founded in 2002, 5AM Ventures actively invests in next-generation life science companies. The firm is currently investing 5AM Ventures IV, L.P., a $250 million venture capital fund that closed in 2013. With $685 million under management, 5AM has invested in over 55 early-stage companies and its successful realizations include DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics (FLXN), Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Incline Therapeutics (acquired by The Medicines Company), Marcadia (acquired by Roche), Novira (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca) and Relypsa (RLYP). For more information, please visit www.5amventures.com.
5AM Venture Management LLC
Andrew Schwab, Managing Partner
Email: [email protected]
Copyright © 2017 5AM Venture Management LLC